Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470443 | 0.90 | TSHR (0.34) | TSHRPDE10APOLBALDH1A1 | |
| SCHEMBL3987619 | 0.90 | TSHR (0.34) | TSHRPDE10APOLBRXFP1TP53 | |
| SCHEMBL3986418 | 0.90 | TSHR (0.34) | TSHRPDE10APOLBALDH1A1 | |
| SCHEMBL4479471 | 0.90 | TSHR (0.34) | TSHRPDE10APOLBRXFP1TP53 | |
| SCHEMBL4470441 | 0.90 | TSHR (0.34) | TSHRPDE10APOLBALDH1A1 | |
| SCHEMBL4479474 | 0.90 | TSHR (0.34) | TSHRPDE10APOLBRXFP1TP53 | |
| SCHEMBL4471099 | 0.89 | TSHR (0.33) | TSHRPDE10A | |
| SCHEMBL6794481 | 0.89 | TSHR (0.33) | TSHRPDE10APOLBRECQLALDH1A1 | |
| SCHEMBL12340534 | 0.88 | TSHR (0.48) | TSHRPDE10APOLBRECQLALDH1A1 | |
| SCHEMBL4473555 | 0.87 | TSHR (0.36) | TSHRPDE10APOLBRXFP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224960-A1 | Pharmaceutical compositions and methods for their use | CYP3A5, CYP3A7, CYP3A43 | TSHR 4432/4885PDE10A 604/4885POLB 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.